Teplizumab

Research use only, not for human use.

Teplizumab (MGA-031) is a humanized monoclonal antibody targeting CD3 that slows the loss of beta cell function and is used to treat type 1 diabetes.

Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes.

Teplizumab (10 ng/mL-10 μg/mL, 5 days) induces human CD8+ T-cell proliferation. Teplizumab (6 days) increases the expression of CD25 and intracellular CTLA4 on CD8+ cells (freshly isolated PBMCs).Cell Proliferation Assay Cell Line:Human PBMCs Concentration:10 ng/mL, 100 ng/mL, 1 μg/mL, 10 μg/mL.Incubation Time: 5 days Result:Induced cell proliferation (measured by incorporation of [3H]thymidine in a 5-day assay.

Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablated the treatment effects of the drug on graft survival in NSG mice.Animal Model:NOD/SCID IL2γc-/- (NSG) mice (a tolergenic humanized mouse model)Dosage:0.24 mg/kg, 5 μg Administration:Intraperitoneal injection (i.p.)Result:Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05.Decreased circulating hCD4 cells in the peripheral blood. Decreased in the proportion of T cells in the bone marrow and lung. Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine.

——

Others

Other Targets

Others

——

——

876387-05-2

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years